发明名称 Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
摘要 The invention provides a combination of a compound having the formula (0) and two or more further anti-cancer agents: or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R<SUP>1</SUP>-A-NR<SUP>4</SUP>- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C-O, NR<SUP>9</SUP>(C-O) or 0(C-O) wherein R<SUP>9 </SUP>is hydrogen or C<SUB>1-4 </SUB>hydrocarbyl optionally substituted by hydroxy or C<SUB>1-4 </SUB>alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R<SUP>1 </SUP>is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C<SUB>1-8 </SUB>hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C<SUB>1-4 </SUB>hydrocarbyloxy, amino, mono- or di-C<SUB>1-4 </SUB>hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO<SUB>2</SUB>; R<SUP>2 </SUP>is hydrogen; halogen; C<SUB>1-4 </SUB>alkoxy (e.g. methoxy); or a C<SUB>1-4 </SUB>hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C<SUB>1-4 </SUB>alkoxy (e.g. methoxy); R<SUP>3 </SUP>is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R<SUP>4 </SUP>is hydrogen or a C<SUB>1-4 </SUB>hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C<SUB>1-4 </SUB>alkoxy (e.g. methoxy).
申请公布号 US2008161355(A1) 申请公布日期 2008.07.03
申请号 US20060814455 申请日期 2006.01.20
申请人 ASTEX THERAPEUTICS LIMITED 发明人 CURRY JAYNE ELIZABETH;LYONS JOHN FRANCIS;SQUIRES MATTHEW SIMON;THOMPSON NEIL THOMAS;THOMPSON KYLA MERRIOM;WYATT PAUL GRAHAM
分类号 A61K31/415;A61K31/454;A61P35/00;A61P35/02 主分类号 A61K31/415
代理机构 代理人
主权项
地址